About Pharmaxis
Pharmaxis is a publicly listed company based in Sydney (Australia) founded in 1998. Drugs for inflammatory and fibrotic diseases are developed. Its chief executive, as recorded, is Gary J Phillips. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is Pharmaxis Ltd.
Company details
Founded in 1998 and based in Sydney, Australia, Pharmaxis operates in the pharmaceutical sector. Focus is placed on developing mechanism-based inhibitors of amine oxidases for various conditions. The pipeline includes Pan-LOX and PXS-5505 targeted at myelofibrosis, liver, and pancreatic cancer; LOXL-2 and PXS-5382 for antifibrotic applications in CKD, IPF, and NASH; Pan-LOX and PXS-6302 for anti-scarring; PXS-4699 for anti-inflammatory muscular dystrophy; and PXS-5370 for multiple anti-inflammatory indications.
- Headquarters Sydney, Australia
- Stage Public
- SectorsHealthcare
- Website pharmaxis.com.au
- Social LinkedIn
- Legal Name Syntara Limited
- Net Profit-$6.2 M (USD)-13.61as on Jun 30, 2026
- EBITDA-$11.16 M (USD)16.66as on Jun 30, 2026
- Latest Funding Round$5M (USD), Post-IPO
Aug 2022
- InvestorsAptar
& 5 more
Funding Insights of Pharmaxis
- Total Rounds 6
- Last Round Post-IPO — $5M
- First Round $1.39M
(Jun 2009)
- Investors Count 6
All 6 funding rounds of Pharmaxis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $5M | Post-IPO | – | – | |
| Apr 2021 | $3.35M | Post-IPO | – | – | |
| Sep 2020 | $733,773 | Grant | – | – | |
| Aug 2018 | $17.74M | Post-IPO | – | – | |
| Jan 2013 | $40M | Post-IPO | – | – | |
| Jun 2009 | $1.39M | Post-IPO | – | – | – |
6 investors in total: 6 institutional.
Investors in Pharmaxis
Pharmaxis has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Aptar, Arix Bioscience and MTPConnect.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Diversified investment management firm | karstpeak.com | Hong Kong, China | ||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Regulatory support, brand differentiation, and prototyping services are provided. | 1992 | aptar.com | Crystal Lake, United States | |
Australia's life sciences innovation is accelerated by MTPConnect. | mtpconnect.org.au | Australia |
Investor details for Pharmaxis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pharmaxis
1 people are tracked at Pharmaxis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Gary J Phillips | CEO | Leadership |
Complete people profiles for Pharmaxis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pharmaxis
Pharmaxis is a publicly listed company on the ASX with ticker symbol SNT in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Oct 2003
- Listed onASX: PXS
- Listed entitySYNTARA LIMITED
- Exchange sectorHealth technology
- ISINAU0000312480
- Share price0.02 AUD (-4% on the day) · 2026-10-14
- Market capitalisation49,112,983.00 AUD
- EPS (diluted, trailing year)-0.01 AUD
- Volume (last session)645,400
Financials of Pharmaxis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | -9.0M AUD | -16.2M AUD | |
| 2025 | -7.9M AUD | -19.4M AUD | |
| 2024 | -20.9M AUD | -18.5M AUD | |
| 2023 | -11.4M AUD | -18.0M AUD | |
| 2022 | 9.8M AUD | -1.9M AUD | -16.7M AUD |
Detailed financial statements for Pharmaxis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pharmaxis
4 dated milestones of Pharmaxis across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Pharmaxis is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.4M.
- Funding Latest funding round, Post-IPO, of $5.0M.
Web traffic of Pharmaxis
Websites that share an audience with Pharmaxis (pharmaxis.com.au).
Websites whose visitors overlap most with Pharmaxis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| emisphere.com | 100% | View details | |||
| crescendobiologics.com | 99% | #13,705,548 | View details | ||
| skyepharma.com | 98% | View details | |||
| kamada.com | 96% | 10.4K | #2,182,321 | View details | |
heartmoves.heartfoundation.org.au | heartmoves.heartfoundation.org.au | 65% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmaxis
Complete news archive for Pharmaxis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmaxis
Pharmaxis was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Pharmaxis is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Gary J Phillips is the CEO of Pharmaxis, as recorded in our data.
Founded in 1998 and based in Sydney, Australia, Pharmaxis operates in the pharmaceutical sector. Focus is placed on developing mechanism-based inhibitors of amine oxidases for various conditions. The pipeline includes Pan-LOX and PXS-5505 targeted at myelofibrosis, liver, and pancreatic cancer; LOXL-2 and PXS-5382 for antifibrotic applications in CKD, IPF, and NASH; Pan-LOX and PXS-6302 for anti-scarring; PXS-4699 for anti-inflammatory muscular dystrophy; and PXS-5370 for multiple anti-inflammatory indications.
Yes, Pharmaxis is publicly traded on ASX under the ticker symbol SNT.
Pharmaxis has 6 investors. Key investors include Aptar, Arix Bioscience, MTPConnect, NovaQuest Capital Management, and Karst Peak Capital.
Pharmaxis operates through Pharmaxis Ltd..